Income statement
USD
Annual
| Metric | 2011 | 2010 | 2009 | 2008 | 2002 |
|---|---|---|---|---|---|
| Revenue | 26K | 83K | 142K | 132K | 207K |
| Gross Profit | 27K | 67K | 118K | 115K | 42K |
| Operating Income | -1M | -3M | -4M | -5M | -650K |
| EBITDA | -930K | -3M | -4M | -5M | -634K |
| Net Income | -1M | -3M | -4M | -5M | 4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Proteonomix, Inc. (PROT) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -68.8%, EPS growth of +72.0%, a dividend yield of 0.0%. What stands out right now is revenue -68.8%, EPS +72.0%, free cash flow +59.6% with operating margin -5026.1% and ROIC 604.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PROT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PROT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PROT Max Drawdown
-99.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PROT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$206.7K
+56.5% YoY
FY Net Income
$4.1M
+182.3% YoY
Free Cash Flow
-$1.1M
-897.5% YoY
Revenue Growth
-68.8%
EPS Growth
+72.0%
Gross Margin
102.0%
Net Margin
-5322.3%
Income statement
USD
| Metric | 2011 | 2010 | 2009 | 2008 | 2002 |
|---|---|---|---|---|---|
| Revenue | 26K | 83K | 142K | 132K | 207K |
| Gross Profit | 27K | 67K | 118K | 115K | 42K |
| Operating Income | -1M | -3M | -4M | -5M | -650K |
| EBITDA | -930K | -3M | -4M | -5M | -634K |
| Net Income | -1M | -3M | -4M | -5M | 4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2011 | 2010 | 2009 | 2008 | 2002 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13 | 18 | 100K | 115 | 24K |
| Total Assets | 3M | 4M | 411K | 420K | 1M |
| Total Liabilities | 7M | 7M | 5M | 8M | 2M |
| Shareholder Equity | -4M | -3M | -4M | -7M | -1M |
| Total Debt | 3M | 4M | 3M | 6M | 182K |
| Net Debt | 3M | 4M | 2M | 6M | 159K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
-897.5% YoY
Capital Expenditures
1
+80.0% YoY
Free Cash Flow
1M
-897.5% YoY
Key ratios
Gross Margin
102.0%
Operating Margin
-5026.1%
Net Margin
-5322.3%
ROE
38.8%
Debt / Equity
-0.94x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.